Navigation Links
Watson Announces Actos(R) Patent Challenge Settlement
Date:3/10/2010

MORRISTOWN, N.J., March 10 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), today announced that it has reached a settlement agreement with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America resolving outstanding patent litigation related to Watson's generic equivalent version of Actos® (Pioglitazone Hydrochloride) 15mg, 30mg and 45mg tablets.  Under terms of the agreement, Takeda granted Watson a non-exclusive royalty free license to its U.S. patents covering Actos®. Under the terms of the agreement, Watson is permitted to launch its generic equivalent version of Actos® on August 17, 2012, or earlier under certain circumstances. 

Actos® had approximately $3.4 billion in brand sales for the twelve months ending December 31, 2009, according to IMS Health. Actos® is a once-daily oral prescription medication that, with diet and exercise, has been shown to be effective for the treatment of type 2 diabetes.

Actos® is a registered trademark of Takeda Chemical Industries, Ltd.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. is a leading global specialty pharmaceutical company.  The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health.  Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, risks that resolution of patent infringement litigation through settlement could result in investigations or actions by private parties or government authorities, including the U.S. Department of Justice and /or the Federal Trade Commission; the difficulty of predicting the timing or outcome of product development efforts and FDA or other regulatory agency approvals or actions, if any; availability and pricing of third-party-sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third-party manufacturers' facilities, products, and/or businesses; the impact of competitive products and pricing, market acceptance of and continued demand for Watson's products; difficulties or delays in manufacturing; and other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2009.

(Logo:  http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)

SOURCE Watson Pharmaceuticals, Inc.

Back to top

RELATED LINKS
http://www.watson.com

'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Confirms Filing of Generic Opana(R) ER Application
2. Watson Signs Agreement to Divest Equity Interest in ScinoPharm
3. Watson to Present at CLSA/Asia USA Investors Forum
4. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
5. Watson Completes Acquisition of Eden Biodesign
6. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
7. Watson Files FDA Application for Generic Rozerem(R)
8. Watson to Present at Credit Suisse Healthcare Conference
9. Watson and Barr Settle Lawsuit Over Oxytrol(R)
10. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
11. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... DUBLIN , Mar 22, 2017 Research ... Packaging Market Analysis & Trends - Industry Forecast to 2025" ... ... at a CAGR of around 7.1% over the next decade to ... analyzes the market estimates and forecasts for all the given segments ...
(Date:3/22/2017)... 22, 2017  Applied BioMath ( www.appliedbiomath.com ), ... research and development, today announced the latest line-up ... 2017 is a day full of presentations, posters, ... (QSP) community. The focus is to learn about ... accelerating drug research and development. The ...
(Date:3/22/2017)... Massachusetts , March 22, 2017 ... solutions, announced today that Newton-Wellesley Hospital, a nationally recognized medical ... significant improvement in patient outcomes following continued implementation of its ... overall reduction of 59% in median nurse response time to ... ...
Breaking Medicine Technology:
(Date:3/23/2017)... Segundo, CA (PRWEB) , ... March 23, 2017 ... ... Verisys FACIS Monthly Monitoring Healthcare products at competitive pricing. Verisys ... source sanctions, Exclusions, Debarments, License restrictions and Disciplinary actions. , “We are delighted ...
(Date:3/23/2017)... Jersey (PRWEB) , ... March 23, 2017 , ... ... of herbal-based and non-steroidal skincare products, was awarded as winners of American Dreams ... products. This competition was hosted jointly by HSN and Good Housekeeping. , ...
(Date:3/23/2017)... ... March 23, 2017 , ... The Boulevard is honored ... 2pm. All events will be located in the Main West Entrance of The ... Child ID event. No appointment is necessary and each child with a parent or ...
(Date:3/23/2017)... , ... March 23, 2017 , ... “Beyond and Back”: ... and Back” is the creation of published author Bonetta Rose, a wife, mother and ... lives. , Published by Christian Faith Publishing, Bonetta Rose‘s new book presents actual events ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... selected HealthiPASS, an innovative patient - centric payment system, to expand its focus ... improvements in the patient financial experience. , “At Ogden Clinic, we are ...
Breaking Medicine News(10 mins):